Results 211 to 220 of about 387,352 (250)
Some of the next articles are maybe not open access.
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
BioDrugs, 2020The inflammatory bowel diseases (IBDs) are chronic immune-mediated inflammatory disorders, including ulcerative colitis (UC) and Crohn's disease (CD). IBD results from a complex interplay between environmental, microbial, and genetic factors to create an abnormal immunological response leading to intestinal inflammation.
Ahmed Almradi +6 more
openaire +2 more sources
IL-17 and IL-23 inhibitors and targeted synthetic DMARDs
2023Abstract Many novel drugs are revolutionizing the care of people with SpA, especially for those who fail to respond to TNFi. IL-17 inhibitors secukinumab (Cosentyx®) and ixekizumab (Taltz®) are very effective for treating people with AS/axSpA, psoriasis, and PsA, but they are not effective for IBD.
openaire +1 more source
Time to lift the moratorium on IL-23 inhibitors for axial psoriatic arthritis
The Lancet RheumatologyThe disappointment stemming from IL-23 inhibition failure in axial spondyloarthritis has resulted in expert panels extrapolating these results to axial psoriatic arthritis, with recommendations against the use of IL-23 inhibitors in this setting. However, post-hoc analyses of clinical trials show clinical improvements in axial psoriatic arthritis ...
Antonio, Tonutti +4 more
openaire +2 more sources
Psoriatic erythroderma and the efficacy of the IL-23 inhibitor guselkumab in clinical practice
Medical alphabetPsoriatic erythroderma is the most severe and rare form of psoriasis, with damage to at least 90 % of the body surface area. Most often, psoriatic erythroderma develops in patients with uncontrolled psoriasis and without timely treatment becomes a potentially life-threatening condition. Against the background of generalized damage to the skin, there is
I. S. Vladimirova, L. S. Kruglova
openaire +1 more source
Psoriasis-Arthritis: Zulassung für IL-23-Inhibitor
hautnah dermatologie, 2021openaire +1 more source
New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Cutis, 2017As immune-related pathways involved in the pathogenesis of psoriasis are elucidated, new biologic treatments targeting these steps of the psoriatic immune cascade are developed. In this article, we review the literature on IL-23 and IL-17 inhibitors in the pipeline for use in moderate to severe psoriasis. Numerous pipeline biologic therapies, including
Joanna, Dong, Gary, Goldenberg
openaire +1 more source
ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY
2023MORA JORGE RODRIGO +3 more
openaire +2 more sources
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Ca-A Cancer Journal for Clinicians, 2011Johann S de Bono +2 more
exaly
Cysteine Proteases and Their Inhibitors
Chemical Reviews, 1997Tanja Schirmeister, Hans-Hartwig Otto
exaly